Loading page…

Emmessar Biotech & Nutrition Ltd (EMMESSA) · mywealthgrid

About

Emmessar Biotech & Nutrition Ltd operates in Commodity Chemicals within the Materials sector.

Face value: ₹10

Market cap

₹11 Cr

P/E

7.9×

P/B

1.4×

Dividend yield

ROE

5.6%

ROCE

6.5%

Debt / equity

OPM

-367.6%

EPS (TTM)

₹2.9

Book value

₹16.2

52-week high

₹35.4

52-week low

₹20.0

₹23.0-35.1%1Y

Beta

0.92

Moves with the index

Volatility (1y)

54%

Annualised, daily returns

RSI (14)

41.1

Neither overbought nor oversold

Rel. strength (1y)

-43.4%

Behind the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Almost debt-free (debt/equity 0)

Cons

−Low return on equity of 6.8% (3-yr avg)
−Profit declined 21.2% a year over the last 5 years
−Revenue shrank over the last 5 years (-44.4% a year)

Research score

Structured signal from quality, growth, valuation and momentum.

41/100

Business quality: 27
Growth: 33
Valuation: 92

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Deepak Fertilizers And Petrochemicals Corporation LimitedDEEPAKFERTDEEPAKFERT	₹16,417 Cr	₹21,903 Cr	₹12,104 Cr	₹2,016 Cr	14.6%	₹984 Cr	6.4%	12.6%	11.3%	55
Tata Chemicals LimitedTATACHEMTATACHEM	₹15,487 Cr	₹23,488 Cr	₹15,120 Cr	₹1,711 Cr	12.4%	₹-2,165 Cr	-11.8%	2.9%	-8.9%	113
Gujarat Narmada Valley Fertilizers And Chemicals LimitedGNFCGNFC	₹8,655 Cr	₹8,655 Cr	₹8,410 Cr	₹1,241 Cr	11.3%	₹1,037 Cr	10.4%	10.6%	9.1%	81
TANFAC Industries LtdTANFACINDTANFACIND	₹6,909 Cr	₹7,002 Cr	₹711 Cr	₹112 Cr	15.8%	₹70 Cr	9.9%	27.7%	20.5%	112
Gujarat Alkalies And Chemicals LimitedGUJALKALIGUJALKALI	₹4,430 Cr	₹4,998 Cr	₹4,498 Cr	₹510 Cr	9.3%	₹66 Cr	-0.1%	1.6%	-0%	25
Grauer & Weil India LimitedGRAUWEILGRAUWEIL	₹3,709 Cr	₹3,717 Cr	₹1,134 Cr	₹188 Cr	16.6%	₹69 Cr	13.9%	23%	18%	72
Ghcl LimitedGHCLGHCL	₹3,700 Cr	₹3,762 Cr	₹3,064 Cr	₹689 Cr	22.5%	₹472 Cr	15.4%	17%	13.4%	126
J.g.chemicals LimitedJGCHEMJGCHEM	₹2,392 Cr	₹2,399 Cr	₹1,071 Cr	₹96 Cr	8.4%	₹75 Cr	7.1%	18.2%	13.3%	101
Thirumalai Chemicals LimitedTIRUMALCHMTIRUMALCHM	₹1,764 Cr	₹3,857 Cr	₹1,832 Cr	₹20 Cr	-2%	₹-152 Cr	-9.7%	-3.3%	-12.3%	14
Ig Petrochemicals LimitedIGPLIGPL	₹1,754 Cr	₹2,110 Cr	₹2,073 Cr	₹207 Cr	4.9%	₹82 Cr	0.1%	3.2%	0.2%	23
Indo Borax & Chemicals LimitedINDOBORAXINDOBORAX	₹1,507 Cr	₹1,507 Cr	₹232 Cr	₹52 Cr	20.5%	₹56 Cr	23.3%	15.5%	15.1%	110
Innovassynth Technologies (India) LtdINOVSYNTHINOVSYNTH	₹1,462 Cr	₹1,466 Cr	₹0 Cr	₹-0 Cr	—	₹-5 Cr	—	-1.1%	-12%	—

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	2	3	1	1	3	7	0	1	1	1	0
COGS	—	-1	-1	-0	-2	4	0	0	0	0	0
Gross profit	—	—	—	—	—	3	0	1	0	0	0
	2	4	2	1	5	3	1	1	1	1	2
	-0	0	-0	-1	-0	1	-1	-1	-1	-1	-1
OPM %	-1.5%	7.6%	-34.4%	-103.2%	-12.1%	12.2%	-250%	-67.7%	-191.1%	-155.7%	-367.6%
Depreciation	—	—	0	0	0	0	0	0	0	0	0
Interest	—	—	—	—	—	0	0	0	0	0	0
	0	1	1	1	1	1	2	2	2	2	2
Profit before tax	0	1	1	0	1	2	1	1	1	1	1
Tax	—	—	—	—	—	1	0	0	0	1	0
Tax %	—	—	—	—	—	35.6%	49.5%	47.4%	7.4%	66.7%	24.1%
	-0	1	1	1	1	1	0	1	1	0	0
PAT margin %	-23.4%	44.9%	70.4%	84.1%	22.1%	20.7%	133.3%	49%	133.9%	52.5%	118.9%
EPS (₹)	—	2.4	1.8	1.1	1.5	2.9	—	—	—	—	0.8
EPS adjusted (₹)	—	—	—	—	—	2.9	1	1	1.5	0.6	0.9
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	5	5	5	5	5	5
Reserves	1	1	2	2	3	3
	0	0	0	0	0	0
	2	1	1	1	2	1
Total equity & liabilities	8	7	8	9	9	10
	1	1	1	1	1	1
CWIP	—	—	—	—	—	0
Investments	1	1	1	1	1	1
	6	5	6	7	7	8
Total assets	8	7	8	9	9	10

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	0	2	0	1	0	-0
	0	-3	-1	-1	-0	0
	—	—	—	0	0	0
Net cash flow	—	—	—	0	-0	0
Free cash flow	0	2	0	—	—	-0
CFO / Operating profit %	55.3%	—	—	—	—	—

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	49.5%	63.9%	60.8%	64.3%	68.9%	75.7%
EBITDA margin %	-103.2%	-12.1%	12.2%	-250%	-67.7%	-191.1%	-155.7%	-367.6%
EBIT margin %	-115.9%	-13.8%	11.3%	-275%	-76.5%	-208.9%	-172.1%	-394.6%
PAT margin %	84.1%	22.1%	20.7%	133.3%	49%	133.9%	52.5%	118.9%
Working capital
Receivable days	—	—	142	10	4	13	12	20
Inventory days	—	—	7	197	128	164	231	406
Payable days	—	—	52	56	0	18	0	487
NWC days	—	—	97	151	131	159	242	-61
Leverage
Current ratio	—	—	3.85	14.73	14.12	13.66	15.77	20.03
Debt to EBITDA	—	—	0	—	—	—	—	—
Debt to equity	—	—	0	0	0.01	0.01	0	0
Interest coverage	—	—	—	—	—	—	—	—
Asset turnover	—	—	0.9	0.05	0.13	0.06	0.07	0.04
Return ratios
Return on assets %	—	—	18.6%	6.7%	6.3%	8.6%	3.5%	4.6%
Return on capital employed %	—	—	35.3%	14%	13.5%	10.4%	11.3%	6.5%
Return on equity %	—	—	25.4%	7.8%	7.5%	10.1%	4.2%	5.4%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	59.53%	59.53%	59.53%	59.53%	59.53%	59.53%	59.53%	59.53%	59.53%	59.53%	59.53%	59.53%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	40.27%	40.27%	40.27%	40.27%	40.27%	40.27%	40.27%	40.27%	40.27%	40.27%	40.27%	40.27%
No. of shareholders	—	—	—	—	—	—	—	—	7,350	7,244	7,172	7,136

Promoter holding up 0 percentage points since Sep 2023.

11 deals · 9 Aug 2021 – 27 Mar 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
27 Mar 2026	AIMS FINANCIAL VENTURES	Bulk	BSE	Buy	45,000	₹24.72	₹0.11 Cr
27 Mar 2026	PRATIBHA DINESH SHAH	Bulk	BSE	Sell	43,337	₹24.66	₹0.11 Cr
29 Jul 2025	QUANTSEYE AI PRIVATE LIMITED	Bulk	BSE	Sell	25,333	₹29.29	₹0.07 Cr
13 Dec 2024	PRATIBHA DINESH SHAH	Bulk	BSE	Buy	38,181	₹43.60	₹0.17 Cr
13 Dec 2024	SHRENIK DINESH SHAH	Bulk	BSE	Sell	26,000	₹43.60	₹0.11 Cr
12 Nov 2024	SHRENIK DINESH SHAH	Bulk	BSE	Buy	26,000	₹51.50	₹0.13 Cr
12 Nov 2024	AIMS FINANCIAL VENTURES	Bulk	BSE	Sell	25,991	₹51.50	₹0.13 Cr
16 Oct 2024	PRACHI PRAKASH RAKTATE	Bulk	BSE	Buy	32,264	₹63.44	₹0.20 Cr
16 Oct 2024	AIMS FINANCIAL VENTURES	Bulk	BSE	Buy	25,986	₹61.42	₹0.16 Cr
16 Oct 2024	PRACHI PRAKASH RAKTATE	Bulk	BSE	Sell	4,589	₹62.85	₹0.03 Cr

1–10 of 11

1 / 2

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. Srinivasa Raghavan Mathurakavi AyyangarChairman & Managing Director
M S Raghavan AyyangarManaging Director
Jeyavel Balaiah NadarExecutive Director & Chief Financial Officer
Mr. Dinesh Kumar DeoraNon-Executive - Independent Director
Dr. Sarada Srinivasa RaghavanDirector
Dr. Anuradha Srinivasa RaghavanDirector
Mr. Veeraraghava RanganathanNon-Executive - Independent Director
Mr. Milind Sitaram DesaiIndependent Director
Mrs. Priyanka SharmaCompany Secretary and Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Emmessar Biotech & Nutrition Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results7 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

16 announcementsExport CSV

2 Oct 2026, 2:55 pmCompany Update

Newapaper Add For Relodgment Of Shares

General PDF

29 Sept 2026, 2:04 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

29 Sept 2026, 1:28 pmAGM/EGM

Scutinizers Report

AGM PDF

29 Sept 2026, 12:21 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

5 Sept 2026, 11:05 amCompany Update

Newspaper Add

General PDF

4 Sept 2026, 6:16 pmCompany Update

Communication To Shareholders Whose Email Ids Are Not Registered

General PDF

4 Sept 2026, 5:52 pmCompany Update

Communication Sent To Shareholders Holding Physical Shares

General PDF

4 Sept 2026, 5:49 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

Date	Category	Subject	Filing
2 Oct 2026, 2:55 pm	Company Update General	Newapaper Add For Relodgment Of Shares	PDF
29 Sept 2026, 2:04 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF

Loading announcements…

Emmessar Biotech & Nutrition Ltd

Emmessar Biotech & Nutrition Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

1

Announcements

Not in the F&O segment

No fund holdings on record

1

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

Emmessar Biotech & Nutrition Ltd

Emmessar Biotech & Nutrition Ltd

About

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Board meetings1

Announcements

Not in the F&O segment

No fund holdings on record

Board meetings1

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

1

1